AstraZeneca fails to quell doubters

Article Abstract:

AstraZeneca plans a major launch for the company's Nexium drug which is to replace Losec. The company faces competition from producers of generic drugs when Losec ceases to be protected by a patent from 2001. Astra's stock price has been volatile. The company aims to deliver over 15 drug candidates annually by 2003. Meanwhile, Novartis and AstraZeneca are to shed their agrochemicals activities to set up Syngenta, a new company, and that affects the policy of developing a life science company.

Author: Oakey, Dan
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1999
Management, AstraZeneca PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Biotech bargains

Article Abstract:

Biotechnology shares have declined since Mar 2000, but careful investors can still make money out of the sector. The risks can be minimised by making sure a firm has adequate funding, has the right management to get drugs through clinical trials and agrees the right licensing deals.

Author: Oakey, Dan, Grosvenor, Alex
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
Methods, Biotechnology industry, Biotechnology industries, Portfolio management, Securities

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Protein age kicks

Article Abstract:

The scientific and research policies of Oxford Glycosciences are examined in detail. The company's research strategy is explained by Raj Parekh, the key figure in this area.

Author: Oakey, Dan
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
Science and technology policy, Oxford GlycoSciences PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Pharmaceutical industry, Drugs
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.